gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate has been researched along with Aortic Stenosis in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Banypersad, SM; Flett, AS; Fontana, M; Maestrini, V; Moon, JC; Neubauer, S; Piechnik, SK; Roberts, N; Sado, DM; White, SK | 1 |
Bautz, W; Dobritz, M; Fellner, C; Fellner, F; Janka, R; Lang, W; Lenz, M | 1 |
2 other study(ies) available for gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate and Aortic Stenosis
Article | Year |
---|---|
Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR.
Topics: Adult; Aged; Amyloidosis; Aortic Valve Stenosis; Biopsy; Breath Holding; Cardiomyopathy, Hypertrophic; Case-Control Studies; Collagen; Contrast Media; Female; Fibrosis; Heterocyclic Compounds; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Organometallic Compounds; Predictive Value of Tests; Prospective Studies; Reproducibility of Results; Severity of Illness Index | 2012 |
Gd-BOPTA: "the MRA contrast agent of choice"?
Topics: Aortic Valve Stenosis; Chelating Agents; Contrast Media; Gadolinium; Heterocyclic Compounds; Humans; Magnetic Resonance Angiography; Meglumine; Organometallic Compounds; Subclavian Artery; Vascular Diseases | 1999 |